ArticleBMC pharmacology & toxicology2021
The cytotoxicity and apoptotic effects of verbascoside on breast cancer 4T1 cell line.
Article in BMC pharmacology & toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Cytotoxic, Drug-Interaction, and Apoptosis-Associated Effects of β-Boswellic Acid and Doxorubicin in Murine 4T1 TNBC-like Cells.Biomedicines · 2026Article
- Article
- Article
- Verbascoside (VB) Inhibits Ischemic Stroke Progression via Suppression of Cell Damage and Ferroptosis By Targeting LCN2/ALOX5/SLC7A11/GPX4 Expression.Molecular neurobiology · 2025Article
- Targeting Inflammation with Natural Products: A Mechanistic Review of Iridoids from Bulgarian Medicinal Plants.Molecules (Basel, Switzerland) · 2025Review
- Antioxidants Acteoside and Orientin as Emerging Agents in Synergistic Cancer Therapy: A Focus on Innovative Applications.Antioxidants (Basel, Switzerland) · 2025Review
- Acteoside as a multifunctional natural glycoside: therapeutic potential across various diseases.Inflammopharmacology · 2025Review
- Biotechnology Production of Cell Biomass from the EndangeredBiomedicines · 2025Article
- Cytotoxicity-guided isolation of elatostemanosides I-VI fromRSC advances · 2025Article
- Assessment of Cytotoxicity, Impact on Cell Migration and Apoptotic Modulation of Acteoside and Plantamajoside on Human Breast Adenocarcinoma (MCF-7).Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Article
- Verbascoside: comprehensive review of a phenylethanoid macromolecule and its journey from nature to bench.Inflammopharmacology · 2024Review
- The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells.Biomedicines · 2023Article
- Article
- Bioactive Compounds ofBiomolecules · 2023Review
- Effects of the Co-Administration of Morphine and Lipopolysaccharide on Toll-Like Receptor-4/Nuclear Factor Kappa β Signaling Pathway of MDA-MB-231 Breast Cancer Cells.Advanced biomedical research · 2023Article
- The pharmacokinetic property and pharmacological activity of acteoside: A review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Evaluation of Marker Compounds and Biological Activity of In Vitro Regenerated and CommercialEvidence-based complementary and alternative medicine : eCAM · 2022Article
- The Anti-Tumor Efficacy of Verbascoside on Ovarian CancerFrontiers in oncology · 2022Article
- Verbascoside Suppresses Epithelial-Mesenchymal Transition and Mitochondrial Biogenesis by Targeting Anti-senescence Signaling in Castration-resistant Prostate Cancer.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite significant advancements in breast cancer therapy, novel drugs with lower side effects are still being demanded. In this regard, we investigated the anti-cancer features of verbascoside in 4 T1 mouse mammary tumor cell.
methodsFirst, MTT assay was performed with various concentrations (ranging between 5 to 200 μM) of verbascoside and IC50 was calculated. Then the expression of Bax, Bcl-2, and caspase-3 was evaluated in treated 4 T1 cells. In addition, we investigated the expression of TLR4, MyD88, and NF-κB to ascertain the underlying mechanism of the anti-proliferative feature of verbascoside. Also, flow cytometry followed by double PI and Annexin V was conducted to confirm the apoptosis-inducing effect of verbascoside.
resultsOur results from MTT assay showed verbascoside inhibits proliferation of 4 T1 cancer cells (IC50 117 μM) while is safe for normal HEK293T cells. By qRT-PCR, we observed that verbascoside treatment (100, 117 and, 130 μM) increases the expression of caspase-3 and Bax while reduces the expression of Bcl-2. Also, verbascoside (100, 117 and, 130 μM) increased the expression of TLR4 only at 130 μM dose and the expression of MyD88 whereas reduced the expression of NF-κB at mRNA level. Flow cytometry analysis also confirmed verbascoside induces apoptosis in 4 T1 cells at 117 μM.
conclusionTaken together, our data showed verbascoside is a safe natural compound for normal cells while has apoptosis-inducing feature through TLR4 axis on 4 T1 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.